Clinical evaluation of cefotiam in internal medicine, with special reference to infectious disease associated with hematological disorders
Uchida, T.; Matsuda, S.; Tanaka, T.; Muroi, S.; Kimura, H.; Satoh, T.; Yui, T.; Satoh, S.; Fujino, A.; Mita, M.; Yamada, Z.; Kariyone, S.; Yoshida, H.; Kikuta, T.; Miura, N.; Itoh, K.; Ikeda, K.; Nemoto, T.; Hiraguri, M.; Sanbe, M.; Takezawa, M.; Nakamura, Y.; Satoh, Y.; Funayama, S.; Igarashi, T.; Ogiu, A.; Maseki, N.; Komatsu, M.
Japanese Journal of Antibiotics 34(8): 1148-1157
1981
ISSN/ISBN: 0368-2781 PMID: 6275142 Document Number: 174738
Clinical evaluation of cefotiam (panspolin), a new cephem antibiotics, was performed in the infectious disease associated with hematological disorders and in the respiratory system. In hematological dis orders, 40% of good and 25% of fair results were obtained in clinical effects. In respiratory infections, however, 92% of good results were obtained. Opportunistic infection due to Gram-negative bacilli are often experienced in patients with leukemia. Since cefotiam has sufficient bacteriocidal effects in broad spectrum, it would be a good therapeutic agent against infectious diseases associated with hematological disorders.